港股创新药概念走强，歌礼制药一度飙涨超20%，药明合联、药明生物、恒瑞医药等跟涨。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 √ | | --- | --- | --- | --- | --- | | 01672 | 歌礼制药-B ● | 17.140 | +2.810 | 19.61% | | 02268 | 药明合联 | 69.700 | +2.350 | 3.49% | | 02269 | 药明生物 | 33.740 | +0.800 | 2.43% | | 01276 | 恒瑞医药 | 74.100 | +1.550 | 2.14% | | 00867 | 康哲药业 | 13.870 | +0.210 | 1.54% | | 01177 | 中国生物制药 | 6.850 | +0.070 | 1.03% | | 02096 | 先声药业 | 13.850 | +0.140 | 102% | 此番大涨背后，直接催化因素是歌礼制药昨晚公布的一项重磅临床研究结果。 研究显示，口服小分子 GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降达 7.7 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [36]. Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, along with the first version of the Commercial Health Insurance Innovative Drug List, was released on December 7, 2025. This adjustment includes 114 new drugs, of which 50 are classified as Class 1 innovative drugs [3]. - The newly launched Chinese Drug Price Registration System aims to facilitate the global pricing system for innovative drugs and attract high-quality foreign drugs to the Chinese market, benefiting patients [4][5]. - The innovative drug sector is expected to continue its rise, with recommendations to focus on companies with rich pipeline layouts, high-potential innovative drugs, and leading technology platforms [11]. Summary by Sections Industry Developments - The 2025 drug list adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and innovation in China [3]. - The Chinese Drug Price Registration System, launched on December 2, 2025, allows pharmaceutical companies to independently declare drug prices, promoting a more transparent and globalized pricing structure [4][5]. Company Highlights - Yino Pharmaceutical has rapidly emerged in the metabolic disease treatment field since its establishment in 2014, with its core product, Isupreglutide α, receiving approval as a Class 1 innovative drug and entering commercialization [7]. Investment Strategy - The report suggests focusing on companies with diverse pipelines, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group, as well as those with high-potential innovative drugs like Sanofi and Kaiyin Technology [11]. - It also highlights the importance of companies with leading technology platforms, such as Dongcheng Pharmaceutical and WuXi AppTec, as well as upstream companies benefiting from overseas expansion [11]. Market Performance - The pharmaceutical sector experienced a decline of 0.74% last week, ranking 19th among 28 industries, while the Shanghai and Shenzhen 300 Index rose by 1.28% [14][24]. - As of December 5, 2025, the pharmaceutical sector's valuation stands at 29.30 times (TTM), with a premium of 17.46% over the overall A-share market [27].

Group 1 - The core viewpoint of the news highlights the significant increase in the success rate of national medical insurance negotiations, reaching a historical high, which is expected to encourage the development of innovative drugs in China [2] - The 2025 National Medical Insurance Drug List will add 114 new drugs, including 50 first-class innovative drugs, with an overall success rate of 88%, marking a notable increase from 76% in 2024 [1] - The new drug list will officially implement on January 1, 2026, expanding the total number of drugs covered to 3,253, enhancing coverage in key areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2 - Citic Securities believes that the successful negotiation rate for national medical insurance has reached a historical high, and the commercial insurance directory is expected to become an important growth driver, promoting the development of innovative drugs [2] - Guotai Junan Securities indicates that the recent press conference and series of discussions by the medical insurance bureau clarify future policies that support companies in "anti-involution," international expansion, and differentiated innovation, which will benefit the high-quality development of the medical device industry [2] - The China Innovation Drug ETF closely tracks the China Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development to reflect the overall performance of the innovative drug industry [2]

Group 1 - The National Healthcare Security Administration released the first version of the "Medical Insurance + Commercial Insurance Dual Directory" on December 7, which may boost investment enthusiasm for innovative drugs in the short term [1] - The innovative drug sector has seen a recent stock price correction, but the long-term logic of the rise of Chinese innovative drugs remains unchanged, suggesting that investment opportunities in innovative drugs, CXO, and upstream life sciences should be emphasized [1] - High-end medical devices may present turning point opportunities, with pharmaceutical equipment benefiting from the overseas pharmaceutical investment upcycle and the recovery of in-hospital procurement driving business growth [1] Group 2 - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which had a daily fluctuation of 20%, reflecting the overall performance of listed companies engaged in innovative drug research and related businesses in China [1] - The index includes companies from the biopharmaceutical and chemical pharmaceutical sectors, highlighting the high R&D investment and technological innovation characteristics of the Chinese innovative drug industry [1]

板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3922.79 | 13376.53 | 1418.57 | | -1.28 -0.03% | +46.54 +0.35% | -7.68 -0.54% | | 科创50 | 创业板指 | 万得全A | | 1353.91 | 3224.50 | 6322.00 | | +3.12 +0.23% | +34.23 +1.07% | +6.53 +0.10% | | 沪深300 | 中证500 | 中证A500 | | 4624.80 | 7179.66 | 5564.18 | | +3.05 +0.07% | +7.29 +0.10% | +2.81 +0.05% | | 中证1000 | 深证100 | 中证红利 | | 7437.69 | 5895.60 | 5502.05 | ...

近日，国家医疗保障局正式发布《国家基本医疗保险、工伤保险和生育保险药品目录（2025年）》。 值得关注的是，三生制药与上海海和药物研究开发股份有限公司合作的紫杉醇口服溶液成功纳入新版目录，成为本次 医保谈判中罕见的口服细胞毒类创新药之一。该目录将于2026年1月1日正式实施，标志着我国在晚期胃癌治疗模式上 向"居家化、门诊化"迈出关键一步，也为三生制药在肿瘤创新药赛道上打开了全新的增长空间。 图表一： 2025 国家医保目录（节选） | | 紫杉烷类 | | | | | --- | --- | --- | --- | --- | | | | 155 紫杉醇口服溶液 | 2027年12月31日 | 限一线含氟尿嘧啶类方案治疗期间或 治疗后出现疾病进展的晚期胃癌患者 | | XL01CD | | | | | 交银国际指出，更多新药进入目录有助于提升临床用药水平，及创新药行业整体研发回报率；商保资金的引入将为创 新药支付带来重要增量资金，为多元化支付体系的建立奠定基础。 中信建投指出，国家医保谈判成功率创历史新高，商保目录有望成为重要增量，政策鼓励创新药发展。与此同时，中 国创新药管线国际化竞争力持续提升，出海模式 ...

港股方面，三大指数悉数下跌，百度集团、华虹半导体、哔哩哔哩跌幅居前。 | 恒生指数 | 恒生国企 | | 恒生科技 | | | --- | --- | --- | --- | --- | | 25684.64 | 9035.91 | | 5628.08 | | | -80.72 -0.31% | -47.62 -0.52% | | -34.47 -0.61% | | | 恒指期货 | 港股通50 | | 恒生生物科技 | | | 25727 | 3868.99 | | 0.00 | | | -50 -0.19% | -1.96 | -0.05% | 0.00 | 0.00% | 【导读】创新药概念股表现活跃，CPO板块走高 一起来看下最新的市场情况及资讯。 12月9日开盘，A股市场震荡拉升，创业板指涨逾1%，沪指跌0.03%，深成指涨0.35%。 板块上来看，创新药概念股表现活跃，CPO、电子元器件、互联网等板块涨幅居前；而贵金属、海南自贸港、房地产等震荡调整。 | 名称 | 现价 | 涨跌幅 = | 总市值 三 | | --- | --- | --- | --- | | 百度集团-SW | 122.000 ...

Core Viewpoint - The vaccine industry is experiencing a divergence, with some companies struggling while others reach historical highs. The demand for HPV vaccines, particularly the nine-valent HPV vaccine, has become a focal point in the domestic market, highlighting the challenges and opportunities within the industry [2][4]. Group 1: HPV Vaccine Market Dynamics - The end of the pandemic has led to a return to normal growth trajectories for the vaccine industry, but demand has slowed, reinforcing the single-product logic in the sector [2]. - The price of the two-valent HPV vaccine has plummeted, even dropping below the price of a cup of milk tea, due to increased competition and market saturation [4]. - Domestic vaccine companies have seen significant declines in stock prices and performance, with many experiencing over 70% drops, signaling the need for innovation rather than imitation [4][10]. Group 2: GSK's Vaccine Strategy - GSK's vaccine segment is a stable revenue source, with its shingles vaccine projected to generate £3.364 billion in sales by 2024 [6][8]. - The domestic market for shingles vaccines is expected to grow from ¥3.73 billion in 2022 to ¥5.63 billion by the end of 2025, with a compound annual growth rate of 16.4% [8]. - GSK's shingles vaccine is the first approved for immunocompromised adults, filling a significant gap in disease prevention [8]. Group 3: GSK's Financial Performance - GSK's stock has increased by over 50% this year, outperforming competitors like Pfizer and Merck, which have seen minimal growth [11]. - GSK reported a revenue of £24.049 billion (approximately ¥226.5 billion) for the first three quarters of 2023, a 3.4% year-on-year increase, with net profit rising by 135.08% to £5.08 billion (approximately ¥47.8 billion) [11]. - The company has raised its full-year guidance for revenue growth to 6%-7% and adjusted its earnings per share forecast upward to 10%-12% [11]. Group 4: M&A Activity and Future Outlook - GSK is accelerating its global acquisitions, including a $500 million upfront payment to Heng Rui Pharma for exclusive rights to multiple projects [14]. - The company has entered into several agreements for exclusive rights to develop and commercialize new therapies, indicating a robust pipeline and strategic growth [15]. - The future of the vaccine industry may hinge on developing unique products and maintaining competitive advantages, as seen in GSK's approach, which contrasts with the challenges faced by domestic companies [16].

Group 1 - The 2025 Innovative Drug High-Quality Development Conference was held in Guangzhou on December 7, announcing the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog [1] - The adjustment of the National Drug Catalog is the 8th since the establishment of the National Medical Insurance Administration, adding 114 new drugs, including 50 Class 1 innovative drugs [1] - The first edition of the commercial health insurance innovative drug catalog includes 19 drugs, featuring CAR-T cancer treatment drugs and Alzheimer's disease treatment drugs, indicating a sustained rise in innovative drugs from the perspectives of business development, commercialization, and policy [1] Group 2 - The Guotai Innovative Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech [1] - From September 24, 2024, to October 31, 2025, during the market rebound, the Sci-Tech Innovative Drug Index and the Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 143.70% and 135.34% respectively, suggesting that the Sci-Tech Innovative Drug Index may better capture the elasticity of the Sci-Tech Innovation Board when market risk appetite recovers [1]

Group 1 - The three major indices opened lower on December 9, with the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Selected 50 Index (HSSSHID.HK) rising over 1%, driven by significant gains in stocks like Zhaoyan New Drug and WuXi AppTec, which both increased by over 10% [1] - The Tianhong Innovative Drug ETF (517380) showed strength with a real-time premium rate of 0.17%, and it recorded a net inflow of 15.58 million yuan on the previous trading day, marking eight consecutive days of net inflows totaling 113 million yuan [1] - The new National Medical Insurance Drug List, effective from January 1, 2026, adds 114 new drugs, including 50 Class 1 innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives, increasing the total number of drugs in the list to 3,253 [1] Group 2 - The Tianhong Innovative Drug ETF tracks the Hang Seng Hong Kong-Shenzhen Innovative Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization, allowing for investment in both A-share and Hong Kong stocks in innovative drugs and CXO leading enterprises [2] - CITIC Securities believes that the success rate of national medical insurance negotiations is at a record high, and the commercial insurance directory is expected to become an important growth driver, with policies encouraging the development of innovative drugs [2] - The international competitiveness of China's innovative drug pipeline continues to improve, with ongoing upgrades in overseas expansion models and new technologies driving rapid industry development [2]